Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 2, 2011, Pages 177-186

  Shimizu, Yasuo ^a,b   Dobashi, K ^c   Fueki, N ^b   Fueki, M ^b   Okada, T ^b   Tomioka, S ^b   Makino, S ^b   Mori, M ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Jobu Hospital for Respiratory Disease   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

CCL15; Corticosteroids; IL 16; MIP 1 ; Morning peak flow; Omalizumab; Severe asthma

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; CYTOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; IMMUNOGLOBULIN E; INTERLEUKIN 16; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 33; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1DELTA; OMALIZUMAB; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; THYMIC STROMAL LYMPHOPOIETIN; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; IMMUNOLOGIC FACTOR; MACROPHAGE INFLAMMATORY PROTEIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; DISEASE EXACERBATION; DIZZINESS; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; INJECTION SITE SWELLING; LUNG FUNCTION TEST; MALE; PATIENT MONITORING; PEAK EXPIRATORY FLOW; PROTEIN BLOOD LEVEL; SEVERE PERSISTENT ASTHMA; SYMPTOMATOLOGY; VITAL CAPACITY; ASTHMA; BIOSYNTHESIS; DOWN REGULATION; DRUG EFFECT; IMMUNOLOGY; LUNG; MACROPHAGE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; SECRETION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTORS; INTERLEUKIN-16; LUNG; MACROPHAGE INFLAMMATORY PROTEINS; MACROPHAGES; MALE; MIDDLE AGED; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 80052879597     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309-16. (Pubitemid 40293346)
2. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003; 131:46-52. (Pubitemid 36649357)
3. Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009; 64:1728-36.
4. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583-93.
5. Van Rensen EL, Evertse CE, Van Schadewijk WA, Van Wijngaarden S, Ayre G, Mauad T, Hiemstra PS, Sterk PJ, Rabe KF. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009; 64:72-80.
6. Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, Kunkel G, Suttorp N, Seybold J. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006; 117:1493-99. (Pubitemid 43795739)
7. Schroeder JT, Bieneman AP, Chichester KL, Hamilton RG, Xiao H, Saini SS, Liu MC. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol 2010; 125:896-01.
8. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59:701-08. (Pubitemid 38850344)
9. Nopp A, Johansson SG, Adédoyin J, Ankerst J, Palmqvist M, Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010; 65:56-60.
10. Menzella F, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L. Omalizumab: when the non-responder is a late-responder. Eur Ann Allergy Clin Immunol 2009; 41:155-59.
11. Buc M, Dzurilla M, Vrlik M, Bucova M. Immunopathogenesis of bronchial asthma. Arch Immunol Ther Exp (Warsz) 2009; 57:331-44.
12. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH publication 2006.
13. Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, Kosinski M, Pendergraft TB, Jhingran P. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006; 117:549-56. (Pubitemid 43340217)
14. Martin RJ. Nocturnal asthma: circadian rhythms and therapeutic interventions. Am Rev Respir Dis 1993; 147:25-28.
15. Scichilone N, Battaglia S, Olivieri D, Bellia V. The role of small airways in monitoring the response to asthma treatment: what is beyond FEV1? Allergy 2009; 64:1563-69.
16. Vignola AM, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V, Bonsignore G. Airway remodeling in asthma. Chest 2003; 123:417-22.
17. Nelson RP, Lockey RF. Treatment of asthma with glucocorticosteroids. South Med J 1988; 81:761-69.
18. Youn BS, Zhang SM, Lee EK, et al. Molecular cloning of leukotactin-1: a novel human beta-chemokine, a chemoattractant for neutrophils, monocytes, and lymphocytes, and a potent agonist at CC chemokine receptors 1 and 3. J Immunol 1997; 159:5201-05. (Pubitemid 127470044)
19. Gilmartin L, Tarleton CA, Schuyler M, Wilson BS, Oliver JM. A comparison of inflammatory mediators released by basophils of asthmatic and control subjects in response to high-affinity IgE receptor aggregation. Int Arch Allergy Immunol 2008; 145:182-92. (Pubitemid 351301310)
20. Busse WW, Holgate ST. Asthma and Rhinitis. Blackwell scientific publication. Boston 1995.
21. Lee JS, Kim IS. Leukotactin-1/CCL15 induces cell migration and differentiation of human eosinophilic leukemia EoL-1 cells through PKCdelta activation. Mol Biol Rep 2010; 37:2149-56.
22. Center DM, Cruikshank WW. Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated monuclear cells. J Immunol 1982; 128:2563-68. (Pubitemid 12124480)
23. Cruikshank W, Little F. Interleukin-16: the ins and outs of regulating T-cell activation. Crit Rev Immunol 2008; 28:467-83.
24. Lynch EL, Little FF, Wilson KC, Center DM, Cruikshank WW. Immunomodulatory cytokines in asthmatic inflammation. Cytokine Growth Factor Rev 2003; 14:489-02.
25. Laberge S, Pinsonneault S, Ernst P, Olivenstein R, Ghaffar O, Center DM, Hamid Q. Phenotype of IL-16-producing cells in bronchial mucosa: evidence for the human eosinophil and mast cell as cellular sources of IL-16 in asthma. Int Arch Allergy Immunol 1999; 119:120-25. (Pubitemid 29304467)
26. Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007; 37:1277-85. (Pubitemid 47372291)
27. Little FF, De Bie J, Van Oosterhout A, Kornfeld H, Center DM, Cruikshank WW. Immunomodulatory effect of interleukin-16 on allergic airway inflammation. Chest 2003; 123:431-42.
28. Trudelle A, El Bassam S, Pinsonneault S, Mazer B, Laberge S. Interleukin-16 inhibits immunoglobulin e production by B lymphocytes. Int Arch Allergy Immunol 2007; 143:109-18. (Pubitemid 46742347)
29. Moore WC, Meyers DA, Wenzel SE, et al. National Heart, Lung, and Blood Institute's Severe Asthma Research Program: Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315-23.